+357 96 030922
info@marketpublishers.com

Global Multiple Myeloma Monoclonal Antibody Drugs Market Growth 2026-2032

https://marketpublishers.com/r/GB195102D2E9EN.html
Date: October 2026
Pages: 85
Price: US$ 3,660.00 (Single User License)
ID: GB195102D2E9EN

Abstracts

The global Multiple Myeloma Monoclonal Antibody Drugs market size is predicted to grow from US$ 1316 million in 2025 to US$ 2144 million in 2032; it is expected to grow at a CAGR of 7.4% from 2026 to 2032.

Multiple Myeloma Monoclonal Antibody Drugs are biologic therapies specifically designed to target antigens expressed on multiple myeloma cells, including Daratumumab, Elotuzumab, and Isatuximab. These drugs function either by directly inducing cancer cell death or by recruiting the immune system to attack malignant cells. The production of these drugs relies on upstream raw materials such as recombinant DNA constructs, mammalian cell lines (commonly CHO cells), culture media components including amino acids, vitamins, and serum, as well as purification resins. Key components in the manufacturing process include protein A affinity columns, filtration membranes, and formulation excipients for stabilization. Leading suppliers in this field include Janssen Biotech (Johnson & Johnson) for Daratumumab, Bristol Myers Squibb/AbbVie for Elotuzumab, and Sanofi for Isatuximab, all of which maintain integrated capabilities from biologics development and GMP manufacturing to global distribution. In 2024, the global sales volume of multiple myeloma monoclonal antibody drugs amounted to 582,000 units, with an average price of $2,150 per unit.

Regional Market Landscape

The global multiple myeloma monoclonal antibody drug market exhibits a clear regional concentration, with North America accounting for 55% of the market, Europe 20%, Asia-Pacific 15%, and Latin America along with the Middle East and Africa combined at 10%. North America’s dominance stems from a mature healthcare system, a highly developed biopharmaceutical industry, and strong patient purchasing power. Europe

+357 96 030922
info@marketpublishers.com

relies on innovative drug approval frameworks and comprehensive insurance coverage in countries such as Germany, France, and the United Kingdom. The Asia-Pacific market is growing rapidly, driven by Japan, China, and South Korea advancing clinical trials and market access. Latin America and the Middle East and Africa remain smaller markets but show stable growth due to improvements in chronic disease management and healthcare infrastructure.

Major Manufacturers and Industry Competition

The leading manufacturers of multiple myeloma monoclonal antibody drugs include Janssen Biotech, Bristol Myers Squibb, Sanofi. Upstream raw materials and critical components are highly concentrated, relying on recombinant DNA constructs, CHO cell lines, culture media, and purification resins, with protein A affinity columns, filtration membranes, and excipients serving as key production elements, and suppliers such as Cytiva, Sartorius, and Merck KGaA holding leading positions. Downstream, the market is concentrated in hospitals, specialty clinics, and distribution channels, with manufacturers leveraging contract manufacturing and global logistics to maintain supply stability. Industry competition focuses on product differentiation and combination therapy strategies, with companies expanding indications, optimizing dosing regimens, and developing bispecific antibodies to sustain market share.

Technology Trends and Innovation Directions

Current technology trends focus on enhancing antibody specificity and potency, reducing immunogenicity, and improving administration convenience. Bispecific antibodies and antibody-drug conjugates are emerging as key innovation areas, combining immune cell recruitment and tumor-targeting mechanisms. Pharmaceutical companies continue to optimize manufacturing processes to increase expression efficiency and purification yield while adopting automation and digital tools to improve quality control and regulatory compliance.

Policy and Industry Development Drivers

Policy and regulatory frameworks play a crucial role in market development. Accelerated drug approval pathways, insurance coverage, and clinical trial support policies drive rapid industry expansion. Intellectual property protection and biologics patent systems secure returns on R&D investment, while initiatives promoting local innovative drug registration and market access provide clear competitive rules for multinational companies. Market growth is also fueled by rising global healthcare

+357 96 030922
info@marketpublishers.com

demand, population aging, and improvements in cancer screening and treatment capabilities.

Report Scope

LP Information, Inc. (LPI) ' newest research report, the “Multiple Myeloma Monoclonal Antibody Drugs Industry Forecast” looks at past sales and reviews total world Multiple Myeloma Monoclonal Antibody Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Multiple Myeloma Monoclonal Antibody Drugs sales for 2026 through 2032. With Multiple Myeloma Monoclonal Antibody Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Multiple Myeloma Monoclonal Antibody Drugs industry.

This Insight Report provides a comprehensive analysis of the global Multiple Myeloma Monoclonal Antibody Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Multiple Myeloma Monoclonal Antibody Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Multiple Myeloma Monoclonal Antibody Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Multiple Myeloma Monoclonal Antibody Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Multiple Myeloma Monoclonal Antibody Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Multiple Myeloma Monoclonal Antibody Drugs market by product type, application, key manufacturers and key regions and countries.

Market Segmentation

Segmentation by Type:

+357 96 030922
info@marketpublishers.com

Daratumumab

Elotuzumab

Isatuximab

Segmentation by Application:

Hospital

Clinic

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

+357 96 030922
info@marketpublishers.com

- Europe
  - Germany
  - France
  - UK
  - Italy
  - Russia
- Middle East & Africa
  - Egypt
  - South Africa
  - Israel
  - Turkey
  - GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

- Johnson & Johnson
- Sanofi
- Bristol Myers Squibb

Key Questions Addressed in this Report

+357 96 030922
info@marketpublishers.com

What is the 10-year outlook for the global Multiple Myeloma Monoclonal Antibody Drugs market?

What factors are driving Multiple Myeloma Monoclonal Antibody Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Multiple Myeloma Monoclonal Antibody Drugs market opportunities vary by end market size?

How does Multiple Myeloma Monoclonal Antibody Drugs break out by Type, by Application?

+357 96 030922
info@marketpublishers.com

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Multiple Myeloma Monoclonal Antibody Drugs Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Multiple Myeloma Monoclonal Antibody Drugs by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Multiple Myeloma Monoclonal Antibody Drugs by Country/Region, 2021, 2025 & 2032
2.2 Multiple Myeloma Monoclonal Antibody Drugs Segment by Type
  2.2.1 Daratumumab
  2.2.2 Elotuzumab
  2.2.3 Isatuximab
  2.2.4 Multiple Myeloma Monoclonal Antibody Drugs Sales by Type
    2.2.4.1 Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Type (2021-2026)
    2.2.4.2 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue and Market Share by Type (2021-2026)
    2.2.4.3 Global Multiple Myeloma Monoclonal Antibody Drugs Sale Price by Type (2021-2026)
2.3 Multiple Myeloma Monoclonal Antibody Drugs Segment by Application
  2.3.1 Hospital
  2.3.2 Clinic
  2.3.3 Multiple Myeloma Monoclonal Antibody Drugs Sales by Application
    2.3.3.1 Global Multiple Myeloma Monoclonal Antibody Drugs Sale Market Share by Application (2021-2026)
    2.3.3.2 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue and Market

+357 96 030922
info@marketpublishers.com

Share by Application (2021-2026)
2.3.3.3 Global Multiple Myeloma Monoclonal Antibody Drugs Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Multiple Myeloma Monoclonal Antibody Drugs Breakdown Data by Company
3.1.1 Global Multiple Myeloma Monoclonal Antibody Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Company (2021-2026)
3.2 Global Multiple Myeloma Monoclonal Antibody Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Company (2021-2026)
3.2.2 Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Multiple Myeloma Monoclonal Antibody Drugs Sale Price by Company
3.4 Key Manufacturers Multiple Myeloma Monoclonal Antibody Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Multiple Myeloma Monoclonal Antibody Drugs Product Location Distribution
3.4.2 Players Multiple Myeloma Monoclonal Antibody Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR MULTIPLE MYELOMA MONOCLONAL ANTIBODY DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Multiple Myeloma Monoclonal Antibody Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Multiple Myeloma Monoclonal Antibody Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Multiple Myeloma Monoclonal Antibody Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Multiple Myeloma Monoclonal Antibody Drugs Market Size by

+357 96 030922
info@marketpublishers.com

Country/Region (2021-2026)
4.2.1 Global Multiple Myeloma Monoclonal Antibody Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Multiple Myeloma Monoclonal Antibody Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Multiple Myeloma Monoclonal Antibody Drugs Sales Growth
4.4 APAC Multiple Myeloma Monoclonal Antibody Drugs Sales Growth
4.5 Europe Multiple Myeloma Monoclonal Antibody Drugs Sales Growth
4.6 Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales Growth

5 AMERICAS

5.1 Americas Multiple Myeloma Monoclonal Antibody Drugs Sales by Country
5.1.1 Americas Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2021-2026)
5.1.2 Americas Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2021-2026)
5.2 Americas Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2021-2026)
5.3 Americas Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Multiple Myeloma Monoclonal Antibody Drugs Sales by Region
6.1.1 APAC Multiple Myeloma Monoclonal Antibody Drugs Sales by Region (2021-2026)
6.1.2 APAC Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region (2021-2026)
6.2 APAC Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2021-2026)
6.3 APAC Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia

+357 96 030922
info@marketpublishers.com

6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Multiple Myeloma Monoclonal Antibody Drugs by Country
  7.1.1 Europe Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2021-2026)
  7.1.2 Europe Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2021-2026)
7.2 Europe Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2021-2026)
7.3 Europe Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs by Country
  8.1.1 Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

+357 96 030922
info@marketpublishers.com

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Multiple Myeloma Monoclonal Antibody Drugs
10.3 Manufacturing Process Analysis of Multiple Myeloma Monoclonal Antibody Drugs
10.4 Industry Chain Structure of Multiple Myeloma Monoclonal Antibody Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Multiple Myeloma Monoclonal Antibody Drugs Distributors
11.3 Multiple Myeloma Monoclonal Antibody Drugs Customer

12 WORLD FORECAST REVIEW FOR MULTIPLE MYELOMA MONOCLONAL ANTIBODY DRUGS BY GEOGRAPHIC REGION

12.1 Global Multiple Myeloma Monoclonal Antibody Drugs Market Size Forecast by Region
  12.1.1 Global Multiple Myeloma Monoclonal Antibody Drugs Forecast by Region (2027-2032)
  12.1.2 Global Multiple Myeloma Monoclonal Antibody Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Multiple Myeloma Monoclonal Antibody Drugs Forecast by Type (2027-2032)
12.7 Global Multiple Myeloma Monoclonal Antibody Drugs Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

+357 96 030922
info@marketpublishers.com

13.1 Johnson & Johnson
13.1.1 Johnson & Johnson Company Information
13.1.2 Johnson & Johnson Multiple Myeloma Monoclonal Antibody Drugs Product Portfolios and Specifications
13.1.3 Johnson & Johnson Multiple Myeloma Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Johnson & Johnson Main Business Overview
13.1.5 Johnson & Johnson Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Multiple Myeloma Monoclonal Antibody Drugs Product Portfolios and Specifications
13.2.3 Sanofi Multiple Myeloma Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Bristol Myers Squibb
13.3.1 Bristol Myers Squibb Company Information
13.3.2 Bristol Myers Squibb Multiple Myeloma Monoclonal Antibody Drugs Product Portfolios and Specifications
13.3.3 Bristol Myers Squibb Multiple Myeloma Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bristol Myers Squibb Main Business Overview
13.3.5 Bristol Myers Squibb Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. Multiple Myeloma Monoclonal Antibody Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Multiple Myeloma Monoclonal Antibody Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Daratumumab
Table 4. Major Players of Elotuzumab
Table 5. Major Players of Isatuximab
Table 6. Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2021-2026) & (K Units)
Table 7. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Type (2021-2026)
Table 8. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Type (2021-2026) & ($ million)
Table 9. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Type (2021-2026)
Table 10. Global Multiple Myeloma Monoclonal Antibody Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Multiple Myeloma Monoclonal Antibody Drugs Sale by Application (2021-2026) & (K Units)
Table 12. Global Multiple Myeloma Monoclonal Antibody Drugs Sale Market Share by Application (2021-2026)
Table 13. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Application (2021-2026) & ($ million)
Table 14. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Application (2021-2026)
Table 15. Global Multiple Myeloma Monoclonal Antibody Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Company (2021-2026) & (K Units)
Table 17. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Company (2021-2026)
Table 18. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Company (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 20. Global Multiple Myeloma Monoclonal Antibody Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Multiple Myeloma Monoclonal Antibody Drugs Producing Area Distribution and Sales Area
Table 22. Players Multiple Myeloma Monoclonal Antibody Drugs Products Offered
Table 23. Multiple Myeloma Monoclonal Antibody Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share Geographic Region (2021-2026)
Table 28. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Multiple Myeloma Monoclonal Antibody Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country/Region (2021-2026)
Table 32. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2021-2026) & (K Units)
Table 35. Americas Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country (2021-2026)
Table 36. Americas Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2021-2026) & (K Units)
Table 38. Americas Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2021-2026) & (K Units)
Table 39. APAC Multiple Myeloma Monoclonal Antibody Drugs Sales by Region (2021-2026) & (K Units)
Table 40. APAC Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Region (2021-2026)

+357 96 030922
info@marketpublishers.com

Table 41. APAC Multiple Myeloma Monoclonal Antibody Drugs Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2021-2026) & (K Units)
Table 43. APAC Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2021-2026) & (K Units)
Table 44. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2021-2026) & (K Units)
Table 45. Europe Multiple Myeloma Monoclonal Antibody Drugs Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2021-2026) & (K Units)
Table 47. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Multiple Myeloma Monoclonal Antibody Drugs
Table 53. Key Market Challenges & Risks of Multiple Myeloma Monoclonal Antibody Drugs
Table 54. Key Industry Trends of Multiple Myeloma Monoclonal Antibody Drugs
Table 55. Multiple Myeloma Monoclonal Antibody Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Multiple Myeloma Monoclonal Antibody Drugs Distributors List
Table 58. Multiple Myeloma Monoclonal Antibody Drugs Customer List
Table 59. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Multiple Myeloma Monoclonal Antibody Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Multiple Myeloma Monoclonal Antibody Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)

+357 96 030922
info@marketpublishers.com

Table 63. APAC Multiple Myeloma Monoclonal Antibody Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Multiple Myeloma Monoclonal Antibody Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Multiple Myeloma Monoclonal Antibody Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Johnson & Johnson Basic Information, Multiple Myeloma Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Johnson & Johnson Multiple Myeloma Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 75. Johnson & Johnson Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Johnson & Johnson Main Business
Table 77. Johnson & Johnson Latest Developments
Table 78. Sanofi Basic Information, Multiple Myeloma Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Sanofi Multiple Myeloma Monoclonal Antibody Drugs Product Portfolios and Specifications
Table 80. Sanofi Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Sanofi Main Business
Table 82. Sanofi Latest Developments
Table 83. Bristol Myers Squibb Basic Information, Multiple Myeloma Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Bristol Myers Squibb Multiple Myeloma Monoclonal Antibody Drugs Product

+357 96 030922
info@marketpublishers.com

Portfolios and Specifications
Table 85. Bristol Myers Squibb Multiple Myeloma Monoclonal Antibody Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Bristol Myers Squibb Main Business
Table 87. Bristol Myers Squibb Latest Developments

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Multiple Myeloma Monoclonal Antibody Drugs
Figure 2. Multiple Myeloma Monoclonal Antibody Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Multiple Myeloma Monoclonal Antibody Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country/Region (2025)
Figure 10. Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Daratumumab
Figure 12. Product Picture of Elotuzumab
Figure 13. Product Picture of Isatuximab
Figure 14. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Type in 2026
Figure 15. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Type (2021-2026)
Figure 16. Multiple Myeloma Monoclonal Antibody Drugs Consumed in Hospital
Figure 17. Global Multiple Myeloma Monoclonal Antibody Drugs Market: Hospital (2021-2026) & (K Units)
Figure 18. Multiple Myeloma Monoclonal Antibody Drugs Consumed in Clinic
Figure 19. Global Multiple Myeloma Monoclonal Antibody Drugs Market: Clinic (2021-2026) & (K Units)
Figure 20. Global Multiple Myeloma Monoclonal Antibody Drugs Sale Market Share by Application (2025)
Figure 21. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Application in 2026
Figure 22. Multiple Myeloma Monoclonal Antibody Drugs Sales by Company in 2026 (K Units)
Figure 23. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by

+357 96 030922
info@marketpublishers.com

Company in 2026
Figure 24. Multiple Myeloma Monoclonal Antibody Drugs Revenue by Company in 2026 ($ millions)
Figure 25. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Company in 2026
Figure 26. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 27. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Geographic Region in 2026
Figure 28. Americas Multiple Myeloma Monoclonal Antibody Drugs Sales 2021-2026 (K Units)
Figure 29. Americas Multiple Myeloma Monoclonal Antibody Drugs Revenue 2021-2026 ($ millions)
Figure 30. APAC Multiple Myeloma Monoclonal Antibody Drugs Sales 2021-2026 (K Units)
Figure 31. APAC Multiple Myeloma Monoclonal Antibody Drugs Revenue 2021-2026 ($ millions)
Figure 32. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales 2021-2026 (K Units)
Figure 33. Europe Multiple Myeloma Monoclonal Antibody Drugs Revenue 2021-2026 ($ millions)
Figure 34. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales 2021-2026 (K Units)
Figure 35. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Revenue 2021-2026 ($ millions)
Figure 36. Americas Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country in 2026
Figure 37. Americas Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Country (2021-2026)
Figure 38. Americas Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Type (2021-2026)
Figure 39. Americas Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Application (2021-2026)
Figure 40. United States Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 41. Canada Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 42. Mexico Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)

+357 96 030922
info@marketpublishers.com

Figure 43. Brazil Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 44. APAC Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Region in 2026
Figure 45. APAC Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Region (2021-2026)
Figure 46. APAC Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Type (2021-2026)
Figure 47. APAC Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Application (2021-2026)
Figure 48. China Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 49. Japan Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 50. South Korea Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 51. Southeast Asia Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. India Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. Australia Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. China Taiwan Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country in 2026
Figure 56. Europe Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share by Country (2021-2026)
Figure 57. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Type (2021-2026)
Figure 58. Europe Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Application (2021-2026)
Figure 59. Germany Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 60. France Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 61. UK Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. Italy Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth

+357 96 030922
info@marketpublishers.com

2021-2026 ($ millions)
Figure 63. Russia Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Country (2021-2026)
Figure 65. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Type (2021-2026)
Figure 66. Middle East & Africa Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share by Application (2021-2026)
Figure 67. Egypt Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 68. South Africa Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 69. Israel Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. Turkey Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. GCC Countries Multiple Myeloma Monoclonal Antibody Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. Manufacturing Cost Structure Analysis of Multiple Myeloma Monoclonal Antibody Drugs in 2026
Figure 73. Manufacturing Process Analysis of Multiple Myeloma Monoclonal Antibody Drugs
Figure 74. Industry Chain Structure of Multiple Myeloma Monoclonal Antibody Drugs
Figure 75. Channels of Distribution
Figure 76. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Forecast by Region (2027-2032)
Figure 77. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 78. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 79. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 80. Global Multiple Myeloma Monoclonal Antibody Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 81. Global Multiple Myeloma Monoclonal Antibody Drugs Revenue Market Share Forecast by Application (2027-2032)

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Multiple Myeloma Monoclonal Antibody Drugs Market Growth 2026-2032
Product link: https://marketpublishers.com/r/GB195102D2E9EN.html
Price: US$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GB195102D2E9EN.html